Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492830 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00492830: Completed Phase 1 study, sponsored by Tracon Pharmaceuticals.
NCT00492830 is a Phase 1 study that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00492830, a Phase 1 study, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
Interventions
- DRUG TRC093 recombinant humanized IgG1k monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
What the finished NCT00492830 record still lists
NCT00492830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which TRC093 recombinant humanized IgG1k monoclonal antibody is the first listed.
NCT00492830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00492830 about?
NCT00492830 is a clinical study titled "Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors". This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
What is the current status of trial NCT00492830?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2007-06. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00492830?
The interventions under investigation include: TRC093 recombinant humanized IgG1k monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT00492830?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00492830's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia